PD-L1-Fc/Oxi-αCD nanoparticles had a better capacity to target these cells and better therapeutic effects on colitis than PD-L1-Fc, which was most likely due to their specific targeting to inflamed areas that resulted in the accumulation of PD-L1-Fc in colon lesions rather than in other metabolic organs. This evidence concerns the gene CD274 and colitis.